2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.
Peter Martin, MD, chief of the Lymphoma Program at the Meyer Cancer Center and an associate professor of medicine at Weill Cornell Medicine, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma (MCL).
During the 2021 ASCO Annual Meeting, findings from a retrospective, observational, real-world study of 4216 previously untreated patients with MCL were presented. The results revealed discrepancies in practice patterns and treatment recommendations between academic and community settings in this patient population, Martin explains.
For example, approximately 49% of patients 65 years of age or older received bendamustine plus rituximab (Rituxan), whereas approximately 30.5% of patients younger than 65 years received a cytarabine-containing regimen, Martin says.
This disparity may be the result of insufficient communication between academic and community practices to inform best practice patterns, says Martin. Additionally, the patient populations enrolled in clinical trials may not be reflective of general populations in the real-world setting, Martin says. As such, future research studies and educational programs should aim to address these disparities, concludes Martin.